Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 9/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.41 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.41 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952359 | 1.00 | P2RY2 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL29403438 | 1.00 | P2RY2 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL30256684 | 1.00 | P2RY2 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL30256282 | 1.00 | P2RY2 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL541102 | 1.00 | P2RY2 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL10492407 | 1.00 | P2RY2 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL30350351 | 0.90 | P2RY2 (0.39) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL20427395 | 0.89 | SLC29A1 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL800372 | 0.89 | SLC29A1 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13134626 | 0.89 | SLC29A1 (0.41) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136120-A1 | INDUCTION OF IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-05-18 | — | — | US | claimed |
| US-20160051665-A1 | INDUCTION OF IMMUNE RESPONSE | DREXEL UNIVERSITY | 2016-02-25 | — | — | US | claimed |
| US-20130142827-A1 | INDUCTION OF IMMUNE RESPONSE | PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A (US) | 2013-06-06 | — | — | US | claimed |
| WO-2011163593-A2 | INDUCTION OF IMMUNE RESPONSE | PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A DREXEL (US) | 2011-12-29 | — | — | WO | claimed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| EP-1165570-B9 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | claimed |
| US-7148349-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2006-12-12 | — | — | US | claimed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | claimed |
| WO-2022261046-A1 | COMPOSITIONS AND METHODS OF TREATING HEPATITIS D AND HEPATITIS B/HEPATITIS D CO-INFECTIONS WITH PHOSPHORAMIDATE CLEVUDINE PRODRUGS | Antios Therapeutics, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-11082386-B2 | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200220830-A1 | 2'-Fluoro-6'-Methylene Carbocyclic Nucleosides and Methods of Treating Viral Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-20180214464-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | CHIMERIX, INC. | 2018-08-02 | — | — | US | disclosed |
| US-9956239-B2 | Methods of treating retroviral infections and related dosage regimes | CHIMERIX, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9932646-B2 | Detection and use of antiviral resistance mutations | ABL SA (LU) | 2018-04-03 | — | — | US | disclosed |
| EP-1058686-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 2000-12-13 | — | — | EP | disclosed |
| US-6130326-A | Monocyclic L-Nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. (US) | 2000-10-10 | — | — | US | disclosed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999045016-A9 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999045016-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
| WO-1999043691-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214464-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | TPMT, HAVCR2, REV1 | P2RY2 3036/4885P2RY4 2700/4885SLC28A1 134/4885 |
| US-11082386-B2 | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections | HAVCR2, NT5C3B, HCCS | P2RY2 417/4885P2RY4 917/4885SLC28A1 293/4885 |
| US-20200220830-A1 | 2'-Fluoro-6'-Methylene Carbocyclic Nucleosides and Methods of Treating Viral Infections | HAVCR2, NT5C3B, HCCS | P2RY2 479/4885P2RY4 1028/4885SLC28A1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.